Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sangamo Therapeutics, Inc. (SGMO) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI‑generated summaries that help explain their contents. Sangamo is a genomic medicine company listed on the Nasdaq Capital Market, and its filings document clinical, regulatory, financial and listing‑related developments across its Fabry disease and neurology‑focused pipeline.
Investors can review Sangamo’s current reports on Form 8‑K, which the company uses to report material events. Recent 8‑Ks describe positive topline and updated data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST‑920) in Fabry disease, including mean annualized estimated glomerular filtration rate (eGFR) slopes and safety findings, as well as the FDA’s agreement to use eGFR slope as an endpoint for an accelerated approval pathway. Other 8‑Ks cover quarterly financial results, collaboration and license agreements, executive transitions and a Nasdaq notice granting additional time to regain compliance with the minimum bid price requirement.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) provide more detailed information on Sangamo’s research and development expenses, general and administrative costs, cash and cash equivalents, and risk factors related to its genomic medicine programs, collaborations and capital needs. These filings also elaborate on the company’s description of its business as a neurology‑focused genomic medicine company and its reliance on investigational product candidates such as ST‑920, ST‑503 and ST‑506.
On this page, Stock Titan’s tools surface new SGMO filings from EDGAR in near real time and apply AI‑powered analysis to highlight key points, such as clinical endpoints referenced in 8‑Ks, updates on BLA preparation activities, or disclosures about Nasdaq listing compliance. Users can also locate proxy statements and other governance‑related documents to better understand Sangamo’s executive compensation plans and board‑level decisions, as referenced in its SEC filings. This combination of source documents and AI summaries is intended to make it easier to interpret complex regulatory language without replacing the need to read the original filings.
Sangamo Therapeutics (SGMO) reported an insider equity transaction involving its President, CEO and Director. On November 24, 2025, the executive had 7,488 shares of common stock withheld and treated as disposed of at $0.4166 per share to cover mandatory tax obligations tied to a restricted stock unit (RSU) vesting event under the company’s 2018 Equity Incentive Plan. This was not an open-market or discretionary sale.
Following this tax withholding, the executive beneficially owned 2,049,534 shares, including multiple RSU grants that vest over time, such as shares from a February 24, 2023 grant, a January 22, 2024 grant vesting in equal quarterly installments through January 22, 2026, and a February 25, 2025 grant with vesting starting February 25, 2026. All RSU vesting remains contingent on continued service and potential acceleration provisions under the plan.
Sangamo Therapeutics, Inc. executive share transaction disclosure
Sangamo Therapeutics' principal financial officer reported an automatic share transaction related to restricted stock units. On November 24, 2025, 2,544 shares of common stock were surrendered to the company at $0.4166 per share to cover mandatory tax withholding when a portion of a restricted stock unit (RSU) award vested. This is recorded as a disposition to the issuer for reporting purposes but was not a discretionary open-market trade.
After this tax withholding event, the officer beneficially owned 696,718 shares of common stock, including multiple RSU grants that continue to vest over time, subject to continued service and potential acceleration under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics (SGMO) reported a routine insider equity transaction by its SVP-Chief Development Officer on a Form 4. On November 24, 2025, the officer surrendered 2,544 shares of common stock at $0.4166 per share solely to cover mandatory tax withholding on a vesting restricted stock unit (RSU) grant under the company’s 2018 Equity Incentive Plan. This withholding is treated as a disposition to the company for reporting purposes but is not a discretionary open-market trade.
Following this tax withholding event, the officer beneficially owned 719,804 shares of common stock. The explanation notes ongoing RSU vesting schedules from grants made in February 2023, January 2024, and February 2025, all subject to continued service and potential acceleration as provided in the equity plan.
Sangamo Therapeutics (SGMO) reported an insider equity transaction by its Head of Research & Technology on Form 4. On November 24, 2025, 723 shares of common stock were surrendered to the company to cover mandatory tax withholding on a restricted stock unit (RSU) vesting, using the closing stock price of $0.4166 per share. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary market trade.
After this tax withholding, the reporting person beneficially owned 193,791 shares, including shares from several RSU grants that vested or are scheduled to vest under Sangamo’s 2018 Equity Incentive Plan, subject to continuous service and potential acceleration under the plan.
Sangamo Therapeutics (SGMO) reported a sharp step-down in revenue and a wider loss for Q3 2025. Revenue was $581 thousand, down from $49.4 million a year ago, reflecting lower collaboration activity. The quarter’s net loss was $34.9 million (basic and diluted EPS of $(0.11)), versus net income of $10.7 million in Q3 2024. Operating expenses were $36.1 million, with R&D at $28.1 million and G&A at $8.0 million.
Liquidity remains tight with a going concern warning. Cash and cash equivalents were $29.6 million as of September 30, 2025. Net cash used in operating activities was $72.8 million for the nine months. Stockholders’ equity fell to $6.2 million from $22.8 million at year-end 2024. To fund operations, the company raised capital via equity: year-to-date, $37.2 million through its at-the-market program and $21.5 million from a separate common stock issuance; Q3 also included 12.0 million pre-funded warrant exercises. As of November 4, 2025, 336,494,489 common shares were outstanding. Management states there is substantial doubt about the ability to continue as a going concern absent additional financing or partnerships.
Sangamo Therapeutics (SGMO) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and is not incorporated by reference.
Sangamo Therapeutics (SGMO) reported a Nasdaq compliance update. The company received a 180-day extension—until April 27, 2026—to regain compliance with Nasdaq’s Minimum Bid Price Requirement of $1.00 per share. Compliance will be restored if the stock closes at or above $1.00 for at least 10 consecutive trading days before that date.
The extension has no immediate effect on SGMO’s Nasdaq Capital Market listing or SEC reporting. If compliance is not regained by April 27, 2026, Nasdaq may notify the company of a potential delisting, which SGMO could appeal under Nasdaq procedures.
Sangamo Therapeutics (SGMO) insider filing: The SVP–Chief Development Officer reported a routine tax-withholding transaction tied to RSU vesting. On 10/22/2025, 43,741 shares were surrendered at $0.66 under Code F to cover mandatory taxes from an RSU vesting event. Following the transaction, beneficial ownership stands at 722,348 shares (direct).
The filing notes RSU activity and schedules: 45,321 shares vested on 10/22/2025 from a 1/22/2024 grant; 89,063 shares from that grant are scheduled to vest in equal quarterly installments through 1/22/2026. It also lists 10,020 shares from a 2/24/2023 grant vesting quarterly through 2/24/2026 and 120,000 shares from a 2/25/2025 grant vesting one-fourth on 2/25/2026 with the remainder in eight equal quarterly installments thereafter, each subject to continuous service.
Sangamo Therapeutics (SGMO) reported an insider transaction on Form 4. The company’s SVP, Chief Legal Officer and Secretary executed a tax-withholding disposition tied to RSU vesting on 10/22/2025. 44,122 shares of common stock were withheld (code F) at $0.66 per share using the issuer’s closing price. Following the transaction, the reporting person beneficially owns 704,121 shares, held directly.
The filing notes these shares were surrendered solely to cover taxes upon vesting under the Amended and Restated 2018 Equity Incentive Plan and do not reflect an open-market sale. It also outlines remaining RSU vesting schedules, including portions from grants dated 1/22/2024, 2/24/2023, and 2/25/2025, subject to continuous service and plan terms.
Sangamo Therapeutics (SGMO) insider filing: the President, CEO and Director reported an automatic share withholding tied to RSU vesting. On October 22, 2025, 126,950 shares were withheld for mandatory taxes at a price of $0.66 per share, following the vesting of a portion of a restricted stock unit grant. After these transactions, the reporting person beneficially owned 2,057,022 shares, held directly.
The filing notes RSU schedules: 123,050 shares resulted from the October 22, 2025 vesting installment of a January 22, 2024 grant, with the remaining 250,000 shares vesting in equal quarterly installments through January 22, 2026. It also includes 29,494 shares from a February 24, 2023 grant vesting in equal quarterly installments through February 24, 2026, and 375,000 shares from a February 25, 2025 grant vesting one-fourth on February 25, 2026, with the balance in eight successive equal quarterly installments thereafter. All vesting is subject to continuous service and the plan’s terms.